Hycamtin Approved For Ovarian Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

PHILADELPHIA--SmithKline Beecham's Hycamtin (topotecan) has received marketing clearance from the FDA for the treatment of patients with metastatic ovarian cancer after failure of initial or subsequent chemotherapy. It is the first topoisomerase I inhibitor approved for use in the United States.

PHILADELPHIA--SmithKline Beecham's Hycamtin (topotecan) has receivedmarketing clearance from the FDA for the treatment of patientswith metastatic ovarian cancer after failure of initial or subsequentchemotherapy. It is the first topoisomerase I inhibitor approvedfor use in the United States.

Hycamtin is currently available in pharmacies and will receiveits official launch by SmithKline shortly. (Look for a New Productreport next month).

The approval was based in part on results from an open, randomizedcomparative study showing that patients treated with Hycamtinhad a significantly longer progression-free survival than patientstreated with paclitaxel (Taxol) and a numerically superior responserate.

[For a more detailed discussion of the pivotal trials, see OncologyNews International, May, 1996,"Panel Recommende HycamtinApproval for Ovarian Cancer".]

Recent Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.